• Users Online: 295
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 33  |  Issue : 3  |  Page : 274-277

Multidose bevacizumab (Avastin) vial microbial safety: A real-life scenario


1 Department of Ophthalmology, Santhiram Medical College and General Hospital, Nandyal, Kurnool, Andhra Pradesh, India
2 Department of Ophthalmology, Consultant of Santhiram Superspeciality Hospital, Nandyal, Kurnool, Andhra Pradesh, India

Correspondence Address:
Dr. Sheshadri Vishnu Mahajan
Department of Ophthalmology, Santhiram Medical College and General Hospital, Nandyal, Kurnool, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/kjo.kjo_189_20

Rights and Permissions

Purpose: The purpose of the study is to evaluate the microbiological safety profile of multidoses of bevacizumab (Avastin) from a single-use vial in a real-life scenario. Methods: In a prospective interventional study, a total of 12 sequential vials of bevacizumab (Avastin) were used for this study. After using each vial for multipuncture, multidoses of intravitreal injections for 1 month, leftover bevacizumab in the vial was again stored in the refrigerator at 4°C. All the vials were sent for microbiological evaluation using Gram staining, potassium hydroxide mount, blood agar, MacConkey agar, and brain–heart infusion broth cultures; both at the opening of each vial and after utilization of 12th vial. Patients receiving intravitreal injections from these vials for various ophthalmic indications were followed up at least 3 months postprocedure for clinical evidence of infection. The Microbiology Laboratory is standardized, especially for ophthalmology specimens, and the media, blood agar and MacConkey, agar were prepared in-house, whereas brain–heart infusion broth is commercial media (HiMedia). Results: All the 12 used vials' microbiological evaluation when evaluated at the opening of vials and 13th month of the study period showed no bacterial or fungal elements. None of the patients who received intravitreal injections from these vials developed clinically detectable ocular infection or inflammation. Conclusion: This study suggests that the contents of multiple-dose bevacizumab (Avastin) vials remain sterile over a period of 1 year without any microbial contamination if proper refrigeration and aseptic precautions are maintained. Multipuncture, multidose Avastin vial utilization with due aseptic precautions and storage shows reliable microbiological safety both in vitro and in vivo over 1 year period.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed146    
    Printed0    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal